Hospital
Southern Baptist Hospital of Florida INC
Southern Baptist Hospital of Florida INC was paid $87.92M by Medicaid between Jan 2018 and Dec 2024, across 482 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoSOUTHERN BAPTIST HOSPITAL OF FLORIDA INC
JACKSONVILLE, FL 32207
JACKSONVILLE, FL 32207
33aNPI1578620449assigned 01/02/2007
33bProvider typeChildren's Hospital
28Total paid$87.92M
24GClaims2,051,316
24DCodes billed482
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Children's Hospital providers in Florida
Rank by total paid#2 of 6
Median peer was paid$668K
This provider vs. median132×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 155,252 | $2.15M | |
| 2019 | 440,761 | $17.24M | |
| 2020 | 409,445 | $18.86M | |
| 2021 | 499,303 | $25.99M | |
| 2022 | 485,464 | $19.84M | |
| 2023 | 51,100 | $3.20M | |
| 2024incomplete | 9,991 | $638K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 127,384 | 109,168 | $11.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 86,359 | 71,178 | $7.91M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 52,123 | 40,908 | $6.06M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.7% | 28,148 | 22,547 | $5.86M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.1% | 27,856 | 9,272 | $4.50M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 39,528 | 35,202 | $3.77M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.5% | 32,511 | 10,626 | $3.05M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 17,545 | 13,570 | $2.72M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 10,871 | 8,951 | $1.95M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 2.2% | 4,353 | 3,810 | $1.92M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 31,181 | 26,075 | $1.88M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 8,765 | 6,805 | $1.87M |
470 more codes
| 93304 | 2.1% | 3,504 | $1.87M | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.8% | 1,959 | $1.61M |
| 80053 | Comprehensive metabolic panel | 1.4% | 52,309 | $1.21M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.3% | 2,828 | $1.13M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 35,929 | $1.04M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 4,479 | $1.04M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 51,648 | $998K |
| 54161 | 1.1% | 1,339 | $983K | |
| 87631 | 1.0% | 10,818 | $907K | |
| 42830 | <1% | 858 | $832K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 11,050 | $806K |
| G0378 | Hospital observation service, per hour | <1% | 19,914 | $730K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15,434 | $710K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,592 | $696K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 19,611 | $557K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,518 | $551K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,657 | $531K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 559 | $519K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,647 | $486K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,042 | $471K |
| 96367 | <1% | 2,417 | $468K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,336 | $446K |
| 87081 | <1% | 13,674 | $437K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 947 | $424K |
| 81025 | <1% | 37,925 | $398K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,507 | $342K |
| 92526 | <1% | 4,431 | $339K | |
| 97161 | <1% | 2,822 | $337K | |
| 44970 | <1% | 68 | $336K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,359 | $329K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,729 | $318K |
| 87088 | <1% | 25,610 | $306K | |
| 93308 | <1% | 1,017 | $285K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,541 | $269K |
| 95782 | <1% | 467 | $256K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,191 | $243K |
| 12011 | <1% | 1,692 | $241K | |
| 76770 | <1% | 2,402 | $241K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,795 | $240K |
| 87430 | <1% | 19,509 | $218K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,309 | $214K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 500 | $207K |
| 92523 | <1% | 1,383 | $203K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,763 | $186K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 44,885 | $179K |
| 82962 | <1% | 9,975 | $178K | |
| 99217 | <1% | 3,580 | $177K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 766 | $173K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,321 | $171K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 98,062 | $168K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,237 | $168K |
| L8613 | Ossicula implant | <1% | 1,853 | $165K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24,652 | $160K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,548 | $159K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,437 | $158K |
| 81002 | <1% | 5,135 | $152K | |
| 12001 | <1% | 1,537 | $150K | |
| 90715 | <1% | 1,975 | $150K | |
| 10060 | <1% | 1,329 | $148K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 168 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,002 | $131K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,072 | $129K |
| 81001 | <1% | 49,580 | $126K | |
| 97162 | <1% | 952 | $126K | |
| 71045 | Radiologic examination, chest; single view | <1% | 31,591 | $125K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,014 | $123K |
| 73610 | <1% | 3,409 | $123K | |
| 73130 | <1% | 3,121 | $120K | |
| 59025 | Fetal non-stress test | <1% | 2,712 | $115K |
| 80305 | <1% | 12,816 | $114K | |
| 92610 | <1% | 986 | $110K | |
| 74019 | <1% | 3,876 | $105K | |
| 73630 | <1% | 4,315 | $104K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,277 | $98K |
| 95700 | <1% | 902 | $98K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,631 | $97K |
| 74018 | <1% | 4,542 | $95K | |
| 74240 | <1% | 562 | $94K | |
| 69210 | <1% | 1,271 | $93K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,765 | $93K |
| 93976 | <1% | 5,705 | $92K | |
| 86850 | <1% | 2,811 | $90K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,425 | $89K |
| 97166 | <1% | 612 | $86K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,070 | $85K |
| 72141 | <1% | 790 | $84K | |
| 99205 | Prolong outpt/office vis | <1% | 1,864 | $83K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,632 | $83K |
| 73090 | <1% | 2,057 | $82K | |
| 96415 | <1% | 500 | $80K | |
| 97597 | <1% | 2,186 | $80K | |
| 87147 | <1% | 1,577 | $79K | |
| 84702 | <1% | 4,549 | $76K | |
| 97165 | <1% | 858 | $73K | |
| 69610 | <1% | 64 | $73K | |
| 95951 | <1% | 313 | $71K | |
| 93321 | <1% | 3,540 | $71K | |
| 87077 | <1% | 6,133 | $70K | |
| 24640 | <1% | 148 | $70K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,051 | $68K |
| 73560 | <1% | 1,883 | $67K | |
| 87040 | <1% | 9,826 | $65K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,835 | $61K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,335 | $60K |
| 70496 | <1% | 1,666 | $60K | |
| 01922 | <1% | 1,472 | $60K | |
| 93975 | <1% | 622 | $57K | |
| 99224 | <1% | 1,439 | $57K | |
| 10061 | <1% | 548 | $55K | |
| 87070 | <1% | 4,026 | $54K | |
| 73110 | <1% | 1,785 | $53K | |
| 76536 | <1% | 833 | $53K | |
| 93017 | <1% | 1,789 | $53K | |
| 73080 | <1% | 1,404 | $52K | |
| 81003 | <1% | 13,445 | $50K | |
| 73030 | <1% | 2,889 | $48K | |
| 93971 | <1% | 3,348 | $48K | |
| 74022 | <1% | 2,974 | $48K | |
| 87210 | <1% | 8,912 | $48K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,916 | $47K |
| 87045 | <1% | 1,253 | $46K | |
| 74230 | <1% | 455 | $46K | |
| 70491 | <1% | 942 | $46K | |
| 80329 | <1% | 2,353 | $45K | |
| 76642 | <1% | 1,114 | $44K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,247 | $44K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,924 | $43K |
| 85007 | <1% | 9,353 | $42K | |
| 73590 | <1% | 1,795 | $40K | |
| 12002 | <1% | 455 | $40K | |
| 73140 | <1% | 888 | $40K | |
| 89051 | <1% | 484 | $39K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,467 | $39K |
| 67311 | <1% | 29 | $38K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,169 | $37K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,058 | $36K |
| 73564 | <1% | 2,389 | $36K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,285 | $35K |
| 99218 | <1% | 3,498 | $34K | |
| 80076 | <1% | 22,341 | $33K | |
| 84484 | <1% | 30,364 | $33K | |
| 70486 | <1% | 1,032 | $31K | |
| 93325 | <1% | 8,839 | $29K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 897 | $29K |
| 76870 | <1% | 657 | $29K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,243 | $28K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,887 | $27K |
| 82728 | <1% | 3,697 | $26K | |
| 83690 | <1% | 24,124 | $25K | |
| 94770 | <1% | 55 | $24K | |
| 86901 | <1% | 6,905 | $23K | |
| 29125 | <1% | 1,310 | $23K | |
| 85610 | <1% | 18,612 | $23K | |
| 93970 | <1% | 1,790 | $23K | |
| 73060 | <1% | 471 | $23K | |
| 86140 | <1% | 8,087 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,136 | $22K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,062 | $22K |
| 74174 | <1% | 191 | $21K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 733 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,422 | $21K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,370 | $20K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,368 | $20K |
| 76881 | <1% | 264 | $20K | |
| 72040 | <1% | 710 | $20K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 7,754 | $19K |
| 96409 | <1% | 249 | $19K | |
| 97755 | <1% | 86 | $19K | |
| 73502 | <1% | 1,751 | $18K | |
| 97116 | <1% | 260 | $18K | |
| 76010 | <1% | 264 | $18K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,087 | $18K |
| 76885 | <1% | 93 | $17K | |
| 88307 | <1% | 105 | $16K | |
| 83735 | <1% | 16,557 | $16K | |
| 80061 | Lipid panel | <1% | 5,624 | $16K |
| 71250 | <1% | 1,107 | $16K | |
| 85730 | <1% | 13,884 | $15K | |
| 84703 | <1% | 1,524 | $15K | |
| 82330 | <1% | 618 | $15K | |
| 36592 | <1% | 826 | $15K | |
| 84439 | <1% | 4,029 | $14K | |
| 73552 | <1% | 790 | $14K | |
| 72100 | <1% | 1,684 | $14K | |
| 72146 | <1% | 275 | $14K | |
| 82274 | <1% | 277 | $13K | |
| 83880 | <1% | 8,488 | $13K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 258 | $13K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 504 | $13K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 378 | $13K |
| 36430 | <1% | 1,173 | $13K | |
| 77080 | <1% | 203 | $12K | |
| 92611 | <1% | 256 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 108 | $12K |
| 95713 | <1% | 66 | $12K | |
| 95715 | <1% | 46 | $12K | |
| 84704 | <1% | 2,949 | $12K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,873 | $12K |
| 82565 | <1% | 3,579 | $11K | |
| 72110 | <1% | 1,463 | $11K | |
| 82550 | <1% | 7,633 | $11K | |
| 70360 | <1% | 598 | $11K | |
| 86923 | <1% | 929 | $11K | |
| 85027 | <1% | 10,359 | $11K | |
| 96402 | <1% | 82 | $10K | |
| 87150 | <1% | 653 | $10K | |
| 97542 | <1% | 84 | $10K | |
| 88341 | <1% | 147 | $10K | |
| J3490 | Unclassified drugs | <1% | 776 | $10K |
| 74455 | <1% | 26 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,484 | $10K |
| 71101 | <1% | 334 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,419 | $9K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,995 | $9K |
| 96417 | <1% | 901 | $9K | |
| 83605 | <1% | 8,112 | $9K | |
| 54300 | <1% | 12 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,851 | $9K |
| 25605 | <1% | 16 | $8K | |
| 93225 | <1% | 340 | $8K | |
| 96376 | <1% | 4,275 | $8K | |
| 42821 | <1% | 30 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 257 | $8K |
| 93226 | <1% | 332 | $8K | |
| 31622 | <1% | 12 | $8K | |
| 82150 | <1% | 5,828 | $8K | |
| 83020 | <1% | 1,727 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 905 | $8K |
| 86308 | <1% | 929 | $8K | |
| 70498 | <1% | 1,346 | $7K | |
| C1769 | Guide wire | <1% | 603 | $7K |
| 87205 | <1% | 3,930 | $7K | |
| 84145 | <1% | 2,528 | $7K | |
| 80069 | <1% | 222 | $7K | |
| 69200 | <1% | 26 | $7K | |
| 87641 | <1% | 1,396 | $7K | |
| 29405 | <1% | 28 | $7K | |
| 29515 | <1% | 382 | $7K | |
| 73521 | <1% | 123 | $6K | |
| 92587 | <1% | 517 | $6K | |
| 99234 | <1% | 558 | $6K | |
| 72131 | <1% | 719 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,558 | $6K |
| 88304 | <1% | 727 | $6K | |
| 70543 | <1% | 25 | $6K | |
| 0042T | <1% | 255 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,887 | $6K |
| 90686 | <1% | 379 | $6K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 127 | $6K |
| 72072 | <1% | 437 | $6K | |
| 73620 | <1% | 238 | $5K | |
| 85014 | <1% | 2,220 | $5K | |
| 73100 | <1% | 194 | $5K | |
| 84112 | <1% | 74 | $5K | |
| 87186 | <1% | 6,222 | $5K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 407 | $5K |
| 99201 | <1% | 198 | $5K | |
| 72050 | <1% | 206 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 765 | $5K |
| 86900 | <1% | 3,304 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,238 | $5K |
| 85379 | <1% | 5,625 | $5K | |
| 85046 | <1% | 4,702 | $4K | |
| 82553 | <1% | 2,176 | $4K | |
| 82247 | <1% | 177 | $4K | |
| 85652 | <1% | 8,268 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,421 | $4K |
| 97164 | <1% | 15 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 183 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 117 | $4K |
| 93320 | <1% | 3,496 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,577 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 25 | $4K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 3,134 | $4K |
| 37799 | <1% | 122 | $4K | |
| 73660 | <1% | 45 | $3K | |
| 82803 | <1% | 2,631 | $3K | |
| 84100 | <1% | 5,734 | $3K | |
| 80047 | <1% | 273 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 560 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 202 | $3K |
| 95812 | <1% | 13 | $3K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 5,404 | $3K |
| 87486 | <1% | 774 | $3K | |
| 82607 | <1% | 2,801 | $3K | |
| 97598 | <1% | 36 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 151 | $3K |
| 77065 | Tomosynthesis, mammo | <1% | 267 | $3K |
| 73000 | <1% | 54 | $3K | |
| 54360 | <1% | 22 | $3K | |
| 72082 | <1% | 49 | $3K | |
| 82784 | <1% | 388 | $3K | |
| 73700 | <1% | 68 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 350 | $3K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 26 | $3K |
| 00635 | <1% | 12 | $3K | |
| 76000 | <1% | 12 | $3K | |
| 43762 | <1% | 32 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,152 | $2K |
| 97750 | <1% | 17 | $2K | |
| 92522 | <1% | 12 | $2K | |
| 73120 | <1% | 16 | $2K | |
| 83615 | <1% | 2,133 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,092 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $2K |
| 00300 | <1% | 473 | $2K | |
| 29105 | <1% | 164 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 127 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 604 | $2K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,127 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,805 | $2K |
| 77062 | <1% | 30 | $2K | |
| 73070 | <1% | 86 | $2K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 155 | $2K |
| 84132 | <1% | 1,143 | $2K | |
| 72070 | <1% | 53 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 656 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,843 | $1K |
| 82140 | <1% | 509 | $1K | |
| 82947 | <1% | 1,297 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,426 | $1K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 443 | $1K |
| 73562 | <1% | 71 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,734 | $1K |
| 00920 | <1% | 1,767 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,057 | $1K |
| 83540 | <1% | 2,369 | $1K | |
| 76999 | <1% | 14 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 583 | $1K |
| 90937 | <1% | 32 | $1K | |
| 80320 | <1% | 2,733 | $995.50 | |
| 96523 | <1% | 112 | $975.53 | |
| 77075 | <1% | 14 | $955.66 | |
| 80051 | <1% | 1,112 | $948.88 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,649 | $911.40 |
| 12013 | <1% | 16 | $857.84 | |
| J1815 | Injection, insulin, per 5 units | <1% | 796 | $822.88 |
| 90674 | <1% | 124 | $810.98 | |
| 96368 | <1% | 240 | $784.96 | |
| 99499 | <1% | 158 | $743.61 | |
| 36600 | <1% | 555 | $740.48 | |
| 86902 | <1% | 30 | $716.06 | |
| 85018 | <1% | 1,257 | $697.78 | |
| 73600 | <1% | 13 | $690.16 | |
| 96411 | <1% | 76 | $687.87 | |
| 00731 | <1% | 1,267 | $657.25 | |
| 84466 | <1% | 2,295 | $649.27 | |
| 82270 | <1% | 104 | $643.14 | |
| 82746 | <1% | 1,358 | $633.21 | |
| 72158 | <1% | 13 | $622.96 | |
| 99152 | <1% | 97 | $615.55 | |
| 82248 | <1% | 1,916 | $603.02 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,952 | $591.97 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 156 | $585.17 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,444 | $583.90 |
| 82378 | <1% | 119 | $582.29 | |
| 82310 | <1% | 1,113 | $557.41 | |
| 82374 | <1% | 300 | $535.76 | |
| 82570 | <1% | 1,408 | $510.60 | |
| 36591 | <1% | 15 | $510.15 | |
| 0012A | <1% | 268 | $504.29 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 162 | $496.91 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 852 | $488.23 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 804 | $485.20 |
| 0011A | <1% | 237 | $457.40 | |
| 84520 | <1% | 1,293 | $445.02 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 14 | $444.81 |
| 00126 | <1% | 1,524 | $433.51 | |
| 84550 | <1% | 1,268 | $431.46 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,580 | $417.72 |
| 51600 | <1% | 26 | $415.47 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 52 | $402.88 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 84 | $398.77 |
| 00120 | <1% | 98 | $323.03 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 377 | $307.09 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 716 | $292.27 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 380 | $263.83 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 347 | $260.30 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 161 | $260.30 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 173 | $260.12 |
| 88342 | <1% | 607 | $256.63 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 706 | $256.22 |
| 83970 | <1% | 213 | $245.94 | |
| 87176 | <1% | 60 | $219.79 | |
| 84295 | <1% | 460 | $219.08 | |
| 51701 | <1% | 433 | $194.65 | |
| 76937 | <1% | 71 | $189.91 | |
| 84134 | <1% | 22 | $185.99 | |
| 86141 | <1% | 173 | $161.61 | |
| 87015 | <1% | 36 | $142.46 | |
| 81513 | <1% | 33 | $123.54 | |
| 86592 | <1% | 58 | $119.20 | |
| 87529 | <1% | 28 | $118.89 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 36 | $107.59 |
| 94729 | <1% | 19 | $100.94 | |
| 93880 | <1% | 32 | $98.16 | |
| 0001A | <1% | 85 | $96.94 | |
| 84480 | <1% | 48 | $86.40 | |
| 72170 | <1% | 32 | $80.90 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,150 | $76.80 |
| 84156 | <1% | 434 | $71.23 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 106 | $64.25 |
| 82043 | <1% | 353 | $60.80 | |
| 94060 | <1% | 37 | $59.16 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 420 | $48.38 |
| S0028 | Injection, famotidine, 20 mg | <1% | 138 | $42.57 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 18 | $38.23 |
| 93041 | <1% | 30 | $31.24 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 139 | $26.85 |
| 80299 | <1% | 46 | $22.75 | |
| 00400 | <1% | 153 | $20.33 | |
| 82533 | <1% | 65 | $17.98 | |
| 84153 | <1% | 17 | $15.21 | |
| 86300 | <1% | 13 | $10.88 | |
| 84157 | <1% | 28 | $9.61 | |
| 85384 | <1% | 30 | $6.89 | |
| 86780 | <1% | 52 | $3.36 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 18 | $1.58 |
| 99292 | 0% | 154 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 556 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 474 | $0.00 |
| 82077 | 0% | 180 | $0.00 | |
| 01400 | 0% | 13 | $0.00 | |
| 00160 | 0% | 81 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 328 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 364 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,114 | $0.00 |
| 87581 | 0% | 765 | $0.00 | |
| 96377 | 0% | 43 | $0.00 | |
| 00813 | 0% | 97 | $0.00 | |
| 86769 | 0% | 38 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 15 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 22 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 397 | $0.00 |
| 00320 | 0% | 16 | $0.00 | |
| 88108 | 0% | 12 | $0.00 | |
| S5553 | Insulin, long acting; 5 units | 0% | 58 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 35 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 32 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 19 | $0.00 |
| 86945 | 0% | 27 | $0.00 | |
| 82945 | 0% | 16 | $0.00 | |
| 3008F | 0% | 12 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 18 | $0.00 |
| 83519 | 0% | 14 | $0.00 | |
| 84075 | 0% | 30 | $0.00 | |
| 82040 | 0% | 19 | $0.00 | |
| 82657 | 0% | 15 | $0.00 | |
| C1763 | Connective tissue, non-human (includes synthetic) | 0% | 12 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 15 | $0.00 |
| J9370 | Vincristine sulfate, 1 mg | 0% | 276 | $0.00 |
| 00840 | 0% | 561 | $0.00 | |
| 82010 | 0% | 339 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 35 | $0.00 |
| 00140 | 0% | 73 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 14 | $0.00 |
| 80179 | 0% | 140 | $0.00 | |
| 80143 | 0% | 140 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 84 | $0.00 |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 35 | $0.00 |
| 84155 | 0% | 29 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 16 | $0.00 |
| 84146 | 0% | 12 | $0.00 | |
| 00124 | 0% | 12 | $0.00 | |
| 84481 | 0% | 15 | $0.00 | |
| 84460 | 0% | 30 | $0.00 | |
| 0002A | 0% | 58 | $0.00 | |
| 84450 | 0% | 25 | $0.00 | |
| 87481 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYCE, PHILIP (CHIEF REVENUE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Southern Baptist Hospital of Florida, INC | Jacksonville, FL | $3.49M |
| Baptist Medical Center of Nassau INC | Fernandina Beach, FL | $3.46M |
| Southern Baptist Hospital of Florida, INC | Jacksonville, FL | $3.32M |
| Baptist Medical Center of the Beaches, INC | Jacksonville Beach, FL | $3.21M |
| Southern Baptist Hospital of Florida, INC | Fleming Island, FL | $1.70M |
| Southern Baptist Hospital of Florida, INC | Jacksonville, FL | $1.30M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.